Dermal filler advertising rules for med spas and practices

Dermal fillers are among the treatments med spas, dermatology and plastic surgery practices advertise most often: lip filler specials, cheek and jawline packages, under-eye offers and before and after reels. Fillers are medical devices, and FDA approves each product for specific areas of the face or hands and specific ages. An ad can name an area no product is approved for, an age below the labeling, or a result the evidence does not support, without anyone on the team noticing.

This guide covers what FDA says fillers are approved for, how to check a product’s own indications, the uses FDA warns against, and how result claims and before and after photos fit under the FTC Act. For wrinkle relaxer injections, see our guide to neuromodulator and injectable advertising. For fat reduction and body sculpting, see our guide to body contouring marketing. For thread lifts and how thread clearances limit lift claims, see our guide to thread lift advertising rules. For injections sold to dissolve fat under the chin, see our guide to fat-dissolving injection marketing.

The short version

• Fillers are approved device by device and area by area. FDA’s filler page says FDA “reviewed and approved different products for use in specific areas of the face and hands.” A claim for an area is only as good as the indications of the product you inject there.
• Adults only. FDA’s page says fillers are approved for adults 22 years of age or older and that safety is unknown in patients under 22, during pregnancy and while breastfeeding. Do not aim filler ads at teens.
• No body filler. FDA recommends against using dermal fillers or any injectable filler to increase breast or buttock size or fullness of the feet, and says injectable silicone is not approved for any aesthetic procedure.
• FDA’s general page is older than some approvals. It was last updated July 6, 2023 and lists the area around the eyes and the neck among uses it recommends against. FDA’s PMA data shows later approvals for specific products, including under-eye hollows and neck lines. Check the product, not the page.
• “FDA-approved” fits a filler only for its approved indication. Fillers are Class III devices approved through PMA. The approval order we read calls its filler a restricted device subject to 21 USC 352(q), under which a restricted device is misbranded if its advertising is false or misleading in any particular.
• Results and photos need support. How long results last, how natural they look and what a typical patient gets are claims under 15 USC 45, 52 and 55 and 16 CFR 255.2.

What FDA has approved fillers for

FDA’s Dermal Fillers page (content current as of July 6, 2023) describes fillers as “medical device implants approved by the FDA for use in helping to create a smoother and/or fuller appearance in the face, including nasolabial folds (the lines extending from the sides of the nose to the edges of the mouth), cheeks, chin, lips, and back of the hands.” It lists the approved uses in adults 22 or older:

• Absorbable (temporary) fillers: moderate to severe facial wrinkles and skin folds, such as nasolabial folds and perioral lines, and augmentation of lips, cheeks, chin and back of the hand.
• Non-absorbable (permanent) fillers: only nasolabial folds and cheek acne scars.
• Restoration and correction of signs of facial fat loss (lipoatrophy) in people with HIV.
• Correction of contour deficiencies, such as wrinkles and acne scars.

FDA’s device classification data lists dermal implants for aesthetic use (product code LMH) and dermal implants for aesthetic use in the hands (product code PKY) as Class III devices on the PMA pathway. On November 1, 2026, FDA’s PMA data returned 22 original approvals under LMH, from 1981 to July 2026, and 1,063 records in all once supplements are counted. Supplements are how a product adds an area or changes its labeling, which is why the list of approved areas keeps moving.

Check your product’s indications, area by area

Approved areas belong to individual products, not to fillers as a category. Searching FDA’s PMA data for product code LMH on November 1, 2026, we found supplements approving specific products for:

• Infraorbital (under-eye) hollows, in approvals from May 2021 to May 2026, in adults over 21.
• Jawline definition and chin augmentation, in approvals from 2020 to November 2025.
• Temple hollowing, in a March 20, 2026 supplement, in patients over 21.
• Neck lines, in a June 11, 2026 supplement for intradermal and subdermal injection “to reduce neck lines for improvement of neck appearance in adults over the age of 21.”
• Lip augmentation, in several products, most recently an original approval on July 9, 2026 for adults over 21.

FDA’s own filler page, last updated in July 2023, still lists the glabella, nose, periorbital area, forehead and neck among the injection sites it recommends against and calls those uses “not approved by the FDA.” Our search of the same PMA data found no approval naming the glabella or the nose. The safe reading: an area is approved only if the product you inject there has that area in its indications, and the age, depth and technique in that indication apply too. A “liquid nose job” ad names an area for which we found no approved filler.

Practical steps: keep a list of each filler product you stock with its PMA number and the indications from FDA’s PMA database, and match every area in your ads, menus and social posts to a product on that list. Name the treatment by area, not by brand, which also keeps you clear of manufacturer brand rules covered in our neuromodulator guide.

Body filler, silicone and needle-free pens

FDA’s page says: “The FDA recommends against using dermal fillers or any injectable filler for body contouring and enhancement” to increase breast size, increase the size of the buttocks, increase fullness of the feet, or implant into bone, tendon, ligament or muscle. It says injectable silicone “is not approved for any aesthetic procedure including facial and body contouring or enhancement” and can lead to long term pain, infections, scarring, permanent disfigurement, embolism, stroke and death. It also says needle-free devices are not approved by FDA for injecting dermal fillers and that FDA has not approved any dermal fillers for over-the-counter use.

21 USC 396 leaves clinicians free to use a legally marketed device off-label within a practitioner-patient relationship, but says it “shall not change any existing prohibition on the promotion of unapproved uses.” Advertising “non-surgical butt lift with filler”, “filler breast enhancement”, “hyaluron pen lips” or silicone injections promotes uses FDA recommends against or has not approved. Do not run them. If your practice offers surgical procedures or devices for these areas, our body contouring guide covers device claims.

Who should not be in your audience

Filler approvals and FDA’s page set the age at 22 and older, or over 21. Lip filler content travels well on short video platforms with young audiences. Set age targeting to 22 and older in paid campaigns, keep “first lip filler” or “prom” or “back to school” themes out, and do not repost content from people under 22 about their filler. FDA’s page also says safety is unknown in pregnancy and breastfeeding, so leave out “mommy makeover” style filler offers aimed at new parents.

Result claims: duration, natural look, no downtime

FDA’s page says results depend on “the underlying tissue structure and the volume and type of filler used,” that how long the effect lasts depends on the filler material and the area, and that absorbable fillers may need to be repeated. It lists common risks (bruising, redness, swelling, pain, tenderness, itching, rash), less common ones (nodules, infection, necrosis) and calls unintended injection into a blood vessel “the most concerning risk,” with complications that can include vision abnormalities including blindness, and stroke.

• “Lasts up to 2 years”. A duration claim must match the labeling of the product you use, for the area you advertise. One product’s figure is not a category claim, and “up to” invites patients to expect the maximum.
• “Natural results guaranteed” or “no one will know”. Results depend on tissue and technique according to FDA. A guarantee is a claim you cannot support for every patient.
• “No downtime”, “painless”, “zero risk”. FDA lists bruising, swelling and pain as common. Leaving out facts that are material in light of what the ad says can make it misleading under 15 USC 55(a)(1).
• “Permanent filler”. FDA’s page says permanent fillers are approved only for nasolabial folds and cheek acne scars, and that removing filler may be difficult or impossible.
• “Safe for everyone”. FDA’s page lists conditions to raise before treatment, including active skin inflammation or infection, bleeding disorders and severe allergies.

Under 15 USC 52, disseminating a false advertisement to induce the purchase of devices or services is unlawful, and the FTC Health Products Compliance Guidance says health benefit claims need competent and reliable scientific evidence. Because the filler approval order we read designates the product a restricted device, 21 USC 352(q) also treats a restricted device as misbranded if “its advertising is false or misleading in any particular.” Separate duties to include the established name and a brief statement of uses, warnings and side effects, under 21 USC 352(r), fall on the manufacturer, packer or distributor rather than on a practice.

“FDA-approved” is accurate for a filler only together with its approved indication: “FDA-approved for lip augmentation in adults over 21” when your product’s labeling says that. Do not borrow the phrase for an area your product is not approved for, and do not use “FDA-cleared”, which describes 510(k) devices (21 CFR 807.97 explains that clearance does not denote official approval).

Before and after photos and reels

Under 16 CFR 255.2(a), an ad using consumer endorsements is read as representing that the product is effective for the purpose shown, and the advertiser needs substantiation as if it had made the claim directly. Under 16 CFR 255.2(b), an endorsement about a central attribute is likely to be read as representative of what consumers generally achieve, unless the ad clearly and conspicuously discloses the generally expected performance. For filler content, that means:

• Use real patients, with their written permission, and show the same lighting, angle and expression in both photos. No filters or retouching of the treated area.
• Show the timing (“two weeks after treatment”) and say that results vary and how long they generally last for that product and area.
• Do not post before and after content for areas your product is not approved for, or for a patient under 22.
• Do not caption a result with a claim you could not make yourself, such as “no swelling at all”.

Our guide to patient testimonials and before-and-after photos covers consent and privacy for patient photos.

Prices, syringe specials and filler parties

Price ads for fillers are usually per syringe. Say what a syringe is and that the number of syringes depends on the assessment, so a “$399 lips” headline does not become a different price at the chair. A “was $800, now $499” claim needs a former price you actually charged; see our guide to was and now price claims. FDA’s page says having filler injected “should be considered a medical procedure, not a cosmetic treatment” and recommends a licensed provider with experience in dermatology or plastic surgery. Group events that frame injection as a party sit badly with that, and who may inject and where is set by your state.

An example (made up)

This illustration is invented to show how the rules fit together. A med spa’s reel reads: “Liquid nose job + lip flip with filler, no downtime, lasts 2 years! Back to school special, $299. Non-surgical BBL with filler now booking.” The account’s followers skew under 22.

Fixes: the nose offer goes, because we found no filler approval for the nose and FDA’s page lists the nose among sites it recommends against. The non-surgical BBL goes, because FDA recommends against filler to increase buttock size. “Back to school” goes, and paid targeting is set to 22 and older. “No downtime” becomes a line about common short-term bruising and swelling. “Lasts 2 years” becomes the duration in the labeling of the lip product the med spa uses, with “results vary”. The price says it is per syringe and that the number of syringes depends on the assessment. The lip filler content stays, because the product the med spa injects is approved for lip augmentation in adults over 21, and the reel now says so.

Checklist

• Every filler product you stock is listed with its PMA number and its indications from FDA’s PMA database.
• Every area in ads, menus and posts matches an approved indication of a product you inject there.
• No body filler offers (breasts, buttocks, feet), no silicone injections, no needle-free pen fillers.
• Paid targeting set to 22 and older; no youth themes; no reposts from people under 22.
• “FDA-approved” only with the product’s approved indication; never “FDA-cleared” for a filler.
• Duration claims match the product labeling for the area; no guarantees, “permanent” or “no downtime” claims.
• Risks FDA lists are not hidden (15 USC 55(a)(1)).
• Before and after content is real, unretouched, consented, dated and labeled with typical results (16 CFR 255.2).
• Prices state per syringe and that the amount depends on the assessment; former prices were actually charged.
• Who may inject and supervise checked against your own state’s rules.

How we help

We build service pages and campaigns for med spas, dermatology and plastic surgery practices, with filler areas, ages and claims checked against the sources above: website design, healthcare SEO for treatment searches, and lead generation campaigns. We do not give legal opinions on device status or scope of practice, and we are not a law firm.

Sources

• FDA: Dermal Fillers (Soft Tissue Fillers) (content current as of July 6, 2023)
• FDA Product Classification: LMH, implant, dermal, for aesthetic use (Class III, PMA)
• FDA Product Classification: PKY, implant, dermal, for aesthetic use in the hands (Class III, PMA)
• FDA Premarket Approval (PMA) database
• openFDA device PMA and classification data (last updated October 19, 2026)
• FDA approval order, PMA P250016, lip augmentation filler (July 9, 2026)
• 21 USC 352: Misbranded drugs and devices (subsections (q) and (r))
• 21 USC 396: Practice of medicine
• 21 CFR 807.97: Misbranding by reference to premarket notification
• 15 USC 45: Unfair methods of competition unlawful
• 15 USC 52: Dissemination of false advertisements
• 15 USC 55: Additional definitions
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 255.2: Consumer endorsements

More in Cash-pay, aesthetic and wellness care